Hubei Xingfa Chemicals Group (600141) Fair Value & Analysis
Basic Materials · CN · Market cap 41.0B CNY
Analysis
Hubei Xingfa Chemicals Group (600141) currently trades at ¥41.97, while our model-based Fair Value estimate is ¥21.11 — implying the stock looks roughly 49.7% overvalued today. We read business quality at 88/100 (high quality), in the Basic Materials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
About the company
Hubei Xingfa Chemicals Group Co., Ltd., together with its subsidiaries, develops, produces, and sells phosphorus-based chemicals in China and internationally. The company offers phosphoric products, such as phosphoric acid; sodium hexametaphosphate, tripolyphosphate, hypophosphite, monofluorophosphate, trimetaphosphate, and acid pyrophosphate; trisodium phosphate and disodium phosphate food grade; dicalcium, monosodium, dipotassium, tricalcium, and triethyl phosphate; tetrapotassium pyrophosphate, tetrasodium pyrophosphate, and trisodium acid pyrophosphate; tetrakis hydroxymethyl phosphonium sulfate, tetrakis hydroxymethyl phosphonium sulfate-urea, tetrakis hydroxymethyl phosphonium chloride, and tetrakis hydroxymethyl phosphonium chloride-urea; and tris(1-chloro-2-propyl) phosphate and tris(hydroxymethyl) phosphine oxide. It also provides compound food additives; herbicides; organic silicones; fertilizers comprising monoammonium, diammonium phosphate, calcium hypophosphite monohydr…
Open the full interactive analysis →
Similar stocks
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.